Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
暂无分享,去创建一个
C. Klersy | A. Nosari | E. Morra | C. Cesana | L. Barbarano | M. Crugnola | E. Pungolino | L. Gargantini | S. Granata | M. Valentini
[1] R. Kyle,et al. Monoclonal gammopathies of undetermined significance. , 2002, Reviews in clinical and experimental hematology.
[2] L. Michaux,et al. Benign monoclonal gammopathy turning to AL amyloidosis after kidney transplantation. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[3] T. Zemunik,et al. Prognosis in monoclonal gammopathy of undetermined significance , 1997, British journal of haematology.
[4] R. Casale,et al. Risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. , 1997, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[5] J. Laszlo,et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. , 1997, Seminars in hematology.
[6] B. Maldague,et al. Nonmyelomatous monoclonal gammopathy: correlation of bone marrow MR images with laboratory findings and spontaneous clinical outcome. , 1997, Radiology.
[7] L. Baldini,et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. , 1996, Blood.
[8] J. Hermans,et al. Serum neural cell adhesion molecule differentiates multiple myeloma from paraproteinemias due to other causes. , 1996, Blood.
[9] M. Björkholm,et al. Blood clonal B‐cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): association with malignant transformation , 1996, British journal of haematology.
[10] R. Kyle. Monoclonal gammopathy of undetermined significance (MGUS). , 1995, Bailliere's clinical haematology.
[11] J. Coebergh,et al. Malignant transformation of monoclonal gammopathy of undetermined significance among out‐patients of a community hospital in Southeastern Netherlands , 1995, British journal of haematology.
[12] R. Kyle,et al. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. , 1995, Seminars in hematology.
[13] D. Samuel,et al. Monoclonal and oligoclonal gammopathies in liver transplant recipients. , 1994, Transplantation.
[14] R A Kyle,et al. "Benign" monoclonal gammopathy--after 20 to 35 years of follow-up. , 1993, Mayo Clinic proceedings.
[15] A. López-Guillermo,et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance , 1992, British journal of haematology.
[16] P. Gobbi,et al. Serum thymidine kinase in monoclonal gammopathies. A prospective study , 1992, Cancer.
[17] H. Weinstein,et al. Monoclonal and oligoclonal gammopathy after bone marrow transplantation. , 1989, Blood.
[18] A. Haverich,et al. High incidence of monoclonal immunoglobulins in patients after liver or heart transplantation. , 1988, Transplantation.
[19] J. Crawford,et al. Evaluation of monoclonal gammopathies in the "well" elderly. , 1987, The American journal of medicine.
[20] U. Axelsson. A 20-year follow-up study of 64 subjects with M-components. , 2009, Acta medica Scandinavica.
[21] D. Sinclair,et al. The incidence of monoclonal gammopathy in a population over 45 years old determined by isoelectric focusing , 1986, British journal of haematology.
[22] B. Durie. Staging and kinetics of multiple myeloma. , 1982, Seminars in oncology.
[23] R. Valentijn,et al. Monoclonal gammapathies in patients undergoing immunosuppressive treatment after renal transplantation. , 1985, Clinical immunology and immunopathology.
[24] A. Fontana,et al. Monoclonal gammopathy in chronic active hepatitis. , 2008, Liver.
[25] F. Mandelli,et al. Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy , 1984, British journal of haematology.
[26] R. Kyle. 'Benign' monoclonal gammopathy. A misnomer? , 1984, JAMA.
[27] H. Garewal,et al. Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. Katzmann,et al. The clinical aspects of biclonal gammopathies. Review of 57 cases. , 1981, The American journal of medicine.
[29] A. Carter,et al. The Physiopathological Significance of Benign Monoclonal Gammopathy: a Study of 64 Cases , 1980, British journal of haematology.
[30] R. Kyle,et al. Smoldering multiple myeloma. , 1980, The New England journal of medicine.
[31] J. Muller,et al. The evolution of asymptomatic monoclonal gammopathies. A follow-up of 20 cases over periods of 3-14 years. , 2009, Acta medica Scandinavica.
[32] C. Wasastjerna,et al. Clinical features of patients with a serum M component. , 2009, Acta medica Scandinavica.
[33] R. Kyle,et al. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. , 1978, The American journal of medicine.
[34] W. C. Levin,et al. Idiopathic (asymptomatic) monoclonal gammopathies. , 1975, Archives of Internal Medicine.
[35] U. Axelsson,et al. Frequency of pathological proteins (M-components) om 6,995 sera from an adult population. , 2009, Acta medica Scandinavica.